A tighter archive for life-science signals.
Search once, then narrow by source or topic.
<a href="https://www.fiercebiotech.com/medtech/ge-healthcare-acquire-imaging-software-provider-intelerad-23b" hreflang="en">GE HealthCare to acquire imaging software provider Intelerad for $2.3B</a>
With its focus on radiology and cardiology practices, as well as assisting in clinical trials, Intelerad’s outpatient footprint will serve as a complement to GE HealthC...
Roche touts early giredestrant success | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Roche touts early giredestrant success | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Roche reports positive Phase III data of giredestrant for breast cancer - Clinical Trials Arena
Roche reports positive Phase III data of giredestrant for breast cancer Clinical Trials Arena
Roche sizes up first BTK inhibitor approval on Phase III MS victory - Clinical Trials Arena
Roche sizes up first BTK inhibitor approval on Phase III MS victory Clinical Trials Arena
Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint - Clinical Trials Arena
Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint Clinical Trials Arena
Thermo Fisher to buy Clario for $8.8bn - Clinical Trials Arena
Thermo Fisher to buy Clario for $8.8bn Clinical Trials Arena
Roche pushes a novel myeloma target | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Roche pushes a novel myeloma target | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Roche looks earlier with divarasib | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Roche looks earlier with divarasib | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
5,000 patients later Roche scraps its TIGIT | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
5,000 patients later Roche scraps its TIGIT | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page